Cargando…

Effect of preventive treatment on health–related quality of life in episodic migraine

The purpose of our study was to prospectively evaluate the impact of preventive drug treatment on the quality of life of patients with episodic migraine (EM). Quality of life evaluations can enhance traditional measures of therapeutic efficacy. Thirty–five consecutive EM without aura patients attend...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bordini, C. A., da Silva, H. Mariano, Garbelini, R. P., Teixeira, S. O., Speciali, J. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2005
Materias:	Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3452063/ https://www.ncbi.nlm.nih.gov/pubmed/16362711 http://dx.doi.org/10.1007/s10194-005-0233-7

Ejemplares similares

The acute and preventative treatment of episodic migraine
por: Miller, Sarah
Publicado: (2012)

Decreasing the minimal duration of the attack to 1 hour: is this sufficient to increase the sensitivity of the ICHD-II diagnostic criteria for migraine in childhood?
por: Arruda, Marco A., et al.
Publicado: (2004)

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Health–related quality of life (HRQOL) and migraine
por: Apolone, Giovanni, et al.
Publicado: (2001)

The Psychometric Properties of the Persian Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraines
por: Zandifar, Alireza, et al.
Publicado: (2013)

Health-related quality of life among Canadians with migraine
por: Brna, P., et al.
Publicado: (2006)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Haplotypes in candidate genes related to nitric oxide pathway and vascular permeability associated with migraine and aura
por: Gonçalves, Flavia Magazoni, et al.
Publicado: (2012)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

Response Predictors of Repetitive Neuromuscular Magnetic Stimulation in the Preventive Treatment of Episodic Migraine
por: Börner, Corinna, et al.
Publicado: (2022)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Electrophysiological correlates of episodic migraine chronification: evidence for thalamic involvement
por: Coppola, Gianluca, et al.
Publicado: (2013)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Pediatric migraine and episodic syndromes that may be associated with migraine
por: Spiri, Daniele, et al.
Publicado: (2014)

Interventional Procedures in Episodic Migraine
por: Plato, Brian M., et al.
Publicado: (2020)

Episodic Migraine and Older Adults
por: Riggins, Nina, et al.
Publicado: (2022)

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study
por: Shibata, Mamoru, et al.
Publicado: (2020)

Migraine: treatments, comorbidities, and quality of life, in the USA
por: Malone, Christopher D, et al.
Publicado: (2015)

Headache-related health resource utilisation in chronic and episodic migraine across six countries
por: Sanderson, Joanna C, et al.
Publicado: (2013)

Symptomatic SARS-CoV-2 Episodes and Health-Related Quality of Life
por: Alacevich, Caterina, et al.
Publicado: (2023)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Migraine with benign episodic unilateral mydriasis
por: Skeik, Nedaa, et al.
Publicado: (2011)

Sex and Gender Considerations in Episodic Migraine
por: Ahmad, Sarah R., et al.
Publicado: (2022)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

Responsivity of Periaqueductal Gray Connectivity Is Related to Headache Frequency in Episodic Migraine
por: Solstrand Dahlberg, Linda, et al.
Publicado: (2018)

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
por: Ferrari, Michel Dominique, et al.
Publicado: (2022)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
por: Maraia, Zaira, et al.
Publicado: (2021)

The borderland of migraine with aura: episodic unilateral mydriasis
por: Maggioni, F., et al.
Publicado: (2010)

Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
por: Fogang, Yannick Fogoum, et al.
Publicado: (2014)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Alterations in pain processing circuitries in episodic migraine
por: Mungoven, Tiffani J., et al.
Publicado: (2022)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
por: Deng, Hong, et al.
Publicado: (2020)

Migraine and quality of life: psychological considerations
por: Andrasik, Frank
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ntnpjrsvp4b8hlooelr4ptd5gl